Article

En ligne (disponible) - Article
Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease / SANTOS, Gustavo Alves Andrade dos ; [et al].
Dementia & neuropsychologia, 2011, vol. 5 (4), p. 332-336.

http://www.demneuropsy.com.br/imageBank/PDF/v5n4a12.pdf... (11-06-2012)

Mots-clés principaux
:
Maladie d'Alzheimer
Pharmacothérapie
Parasympathomimétique

Mots-clés secondaires : Acétylcholine ; Marqueur biologique

Résumé :

Cholinesterase inhibitors (ChE-Is) are among the main drugs approved for the treatment of Alzheimer's disease (AD). Rivastigmine in the form of a transdermal patch is an alternative delivery method, and can give greater treatment compliance.
Objectives: To conduct a preliminary assessment of the neurocognitive and biological effects of oral and transdermal Rivastigmine in patients with AD and to identify a potential biological marker and demonstrate a possible relationship between esterase levels and behavioral scores of AD patients.
Methods: Forty patients with AD were treated with cholinesterase inhibitors (ChE-Is), evaluated using the MMSE and NPI, and simultaneously sampled to determine their serum levels of AChE and BuChE for 180 days.
Results: The differences obtained between oral and transdermal forms, as assessed by the MMSE and NPI scores of the AD patients, were not significant at the three time points examined (0, 90, and 180 days). However, serum BuChE levels of the transdermal group differed significantly (p<0.0004) compared with those of the oral group at 90 days.
Conclusion: Use of a transdermal ChE-I, rivastigmine tartrate significantly reduced BuChE levels in the AD patients studied.

Langue : Anglais
Doc n° : 29741
NumRec : 6317903
 

       

  Copier Permanent URL de cette page Ajouter cette page

     

disponible
Réserver
Pour réserver ce document, vous devez d'abord vous connecter


Aller vers :   IUGM    Fondation IUGM   Centre de recherche IUGM